The Biologic Therapy Program focuses on the use and investigation of the role of various biologic agents, primarily cytokines, in the treatment of solid tumors, such as melanoma and renal cell carcinoma. Treatment is largely protocol based and tightly tied with ongoing NIH-funded laboratory investigations. Under the leadership of Michael B. Atkins, MD , this program is nationally recognized for excellence and was instrumental in the development of current standard approaches to the treatment of melanoma and kidney cancer.
Patients come from all over the country for treatment.
The current clinical trials and related research activities will insure that this program maintains its leadership status for the foreseeable future. The conducting of Phase I trials with laboratory and clinical endpoints will be invaluable to the clinical development and evaluation of novel immunotherapy approaches to treat AIDS related malignancies. For a list of protocols for melanoma or renal cell carcinoma, please visit the current clinical studies page.